Feb 25 (Reuters) - Drugmaker Merck (MRK.N), opens new tab said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government price setting, which would become ...

The combination of Padcev and Keytruda showed promising clinical activity in UTUC patients, with a 25% ORR in primary lesions and 35% in target lesions. The study included 22 patients with intact ...

How Does Keytruda Work for RCC? Some cancer cells have what are called checkpoint proteins known as PD-L1 on their cell surface. Some immune cells in our bodies called T cells have proteins on ...

Pi Network’s native token, PI, dropped more than 65% following the project’s highly anticipated mainnet launch. On Feb. 20, Pi Network announced that its “Open Network” had officially ...

The safety profile of the combination therapy remains consistent, with no new adverse effects observed. Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally ...

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major pathological response in patients with resectable locally advanced head and ...

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its blockbuster cancer drug Keytruda in certain patients with head and neck cancer.

Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028 ...

Pi Network launched its Open Mainnet on February 20, 2025, leading to considerable price fluctuations for Pi Coin. Analysts see significant growth potential if adoption increases, with predictions ...

FDA recently announced new safety requirements for DPD screening in cancer patients. Kristine Ashcraft, founder and CEO of ...

The firm believes the “real culprit” for Merck shares remaining under pressure is Keytruda’s 2028 patent expiration. Despite the company building out its pipeline, past precedence shows the ...

MSD’s checkpoint inhibitor Keytruda has been cleared by the FDA for use in newly diagnosed cervical cancer patients with less severe disease, becoming the first anti-PD-1/PD-L1 immunotherapy for ...